Clinical Trial Update: A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase I study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered CUG252 in healthy volunteers for a program t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• CUG252

Snippet

Sponsor: Cugene Inc. | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: COMPLETED